Global Market Study on Human Insulin: With more people getting diagnosed with Diabetes, the market to be on the expansion spree
Human Insulin Market Analysis 2022-2028
A recent market study published by Persistence Market Research (PMR) on the Human Insulin Market including global industry analysis for 2014-2021 & opportunity assessment for 2022-2028, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the market, growth prospects are obtained with utmost precision.
Human Insulin Market: Segmentation
The global Human Insulin Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Type
Modern Human Insulin
Fast-acting
Long-acting
Premix
Traditional Human Insulin
Long-acting
Short-acting
Fast-acting
Premix
Type of Diabetes
Diabetes Type 1
Diabetes Type 2
Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa (MEA)
Key Questions Answered in Report
The research study offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.
What are the key trends that are continuously shaping market growth?
Which are the prominent regions that offer plentiful opportunities for players in the market?
How has the outbreak of COVID-19 affected the market and what would the trend be like during the forecast period?
What are the differential strategies adopted by key players to hold a significant share in the human insulin industry?
Research Methodology
A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.
The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.
The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Pfizer Inc, Wockhardt, and Julpha, among others.
- 1. Preface
- 1.1. Report Description
- 1.2. Research Methodology
- 1.3. Assumptions
- 2. Market Synopsis
- 3. Porter’s Five Forces Analysis
- 3.1. Bargaining Power of Suppliers
- 3.2. Bargaining Power of Buyers
- 3.3. Threat of New Entrants
- 3.4. Threat of Substitutes
- 3.5. Intensity of Rivalry
- 4. Industry Overview
- 4.1. Market Definition
- 4.2. Market Drivers
- 4.2.1. Growing prevalence of diabetes
- 4.2.2. Technological advancements in human insulin delivery devices
- 4.2.3. Increasing awareness among people towards diabetes care
- 4.3. Impact Analysis of Market Drivers
- 4.4. Market Restraints
- 4.4.1. Uneven pricing and limited access to human insulin in emerging countries
- 4.4.2. Strict regulatory requirements for drug approval
- 4.5. Impact Analysis of Market Restraints
- 4.6. Market Trends
- 4.6.1. Increasing usage of insulin pens for administration of human insulin
- 5. Global Market Size and Forecast
- 6. Market Size and Forecast by Type
- 6.1. Traditional Human Insulin
- 6.2. Modern Human Insulin
- 7. Market Size and Forecast of Traditional Human Insulin by Type
- 7.1. Short-acting Human Insulin
- 7.2. Intermediate-acting Human Insulin
- 7.3. Premixed Human Insulin
- 8. Market Size and Forecast of Modern Human Insulin by Type
- 8.1. Rapid-acting Human Insulin
- 8.2. Long-acting Human Insulin
- 8.3. Premixed Human Insulin
- 9. Market Size and Forecast by Disease
- 9.1. Type 1 Diabetes
- 9.2. Type 2 Diabetes
- 10. Market Size and Forecast by Brand
- 10.1. Traditional Human Insulin Brand
- 10.2. Modern Human Insulin Brand
- 11. Market Size and Forecast by Geography
- 11.1. North America
- 11.1.1. Scenario in the U.S.
- 11.1.2. Scenario in Canada
- 11.2. Europe
- 11.2.1. Scenario in Germany
- 11.2.2. Scenario in France
- 11.2.3. Scenario in the U.K.
- 11.3. Asia Pacific
- 11.3.1. Scenario in Japan
- 11.3.2. Scenario in China
- 11.3.3. Scenario in India
- 12. Pipeline Drugs for Diabetes Treatment
- 12.1. Drugs Under Development for Diabetes Treatment
- 13. Competitive Scenario
- 13.1. Competitive Benchmarking
- 14. Company Profiles
- 14.1. Novo Nordisk A/S
- 14.1.1. Company overview
- 14.1.2. Products and services
- 14.1.3. Financial performance
- 14.1.4. Key developments
- 14.2. Eli Lilly and Company
- 14.2.1. Company overview
- 14.2.2. Products and services
- 14.2.3. Financial performance
- 14.2.4. Key developments
- 14.3. Sanofi
- 14.3.1. Company overview
- 14.3.2. Products and services
- 14.3.3. Financial performance
- 14.3.4. Key developments
- 14.4. Biocon
- 14.4.1. Company overview
- 14.4.2. Products and services
- 14.4.3. Financial performance
- 14.4.4. Key developments
- 14.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 14.5.1. Company overview
- 14.5.2. Products and services
- 14.5.3. Financial performance
- 14.5.4. Key developments
- 14.6. ADOCIA
- 14.6.1. Company overview
- 14.6.2. Products and services
- 14.6.3. Financial performance
- 14.6.4. Key developments
- 14.7. Wockhardt
- 14.7.1. Company overview
- 14.7.2. Products and services
- 14.7.3. Financial performance
- 14.7.4. Key developments
- 14.8. Julphar
- 14.8.1. Company overview
- 14.8.2. Products and services
- 14.8.3. Financial performance
- 14.8.4. Key developments
- 14.9. Merck & Co., Inc.
- 14.9.1. Company overview
- 14.9.2. Products and services
- 14.9.3. Financial performance
- 14.9.4. Key developments
- 14.10. Pfizer, Inc.
- 14.10.1. Company overview
- 14.10.2. Products and services
- 14.10.3. Financial performance
- 14.10.4. Key developments
- 14.11. Bristol-Myers Squibb Company
- 14.11.1. Company overview
- 14.11.2. Products and services
- 14.11.3. Financial performance
- 14.11.4. Key developments
- 14.12. GlaxoSmithKline Plc
- 14.12.1. Company overview
- 14.12.2. Products and services
- 14.12.3. Financial performance
- 14.12.4. Key developments
- 14.13. Oramed Pharmaceuticals, Inc.
- 14.13.1. Company overview
- 14.13.2. Products and services
- 14.13.3. Financial performance
- 14.13.4. Key developments
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook